2-(4-氟苯基)-1,3-噻唑-4-羧酸 | 863668-07-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-氟苯基)-1,3-噻唑-4-羧酸
• 英文名称: 2-(4-fluorophenyl)thiazole-4-carboxylic acid
• 英文别名: 2-p-fluorophenylthiazole-4-carboxylic acid；2-(4-fluorophenyl)-1,3-thiazole-4-carboxylic acid
• CAS: 863668-07-9
• 化学式: C₁₀H₆FNO₂S
• mdl: MFCD07339052
• 分子量: 223.228
• InChiKey: VVZKBCLSODNUDS-UHFFFAOYSA-N

物化性质

• 沸点：
  412.3±51.0 °C(Predicted)
• 密度：
  1.447±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(4-Fluorophenyl)-1,3-thiazole-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(4-Fluorophenyl)-1,3-thiazole-4-carboxylic acid
CAS number: 863668-07-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H6FNO2S
Molecular weight: 223.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-氟苯基)-1,3-噻唑-4-羧酸 在 盐酸 、 lithium aluminium tetrahydride 、 lithium hydroxide monohydrate 、 二乙胺基三氟化硫 、 水 、 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 114.0h， 生成 2,2-difluoro-N-((1R,2R)-1-(8-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-2-(2-(4-fluorophenyl)thiazol-4-yl)acetamide
  参考文献：
  名称：

  [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES
  [FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR LE TRAITEMENT DE MALADIES

  摘要：

  本文描述了一种I式化合物，制备这种化合物的方法，含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与葡萄糖酰胺合成酶（GCS）相关的疾病或症状的方法。

  公开号：

  WO2015042397A1
• 作为产物：
  描述：

  4-氟苯硼酸 在 1,1'-双(二苯基膦)二茂铁 、 四(三苯基膦)钯 、 lithium hydroxide monohydrate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 甲苯 为溶剂， 反应 24.0h， 生成 2-(4-氟苯基)-1,3-噻唑-4-羧酸
  参考文献：
  名称：

  Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

  摘要：

  DOI：

  10.1016/j.bmcl.2021.127846

文献信息

• Rh(<scp>iii</scp>)-catalyzed cyclization reaction of azoles with alkynes: efficient synthesis of azole-fused-pyridines
  作者：Xuebing Chen、Youzhi Wu、Jinyi Xu、Hequan Yao、Aijun Lin、Yue Huang

  DOI：10.1039/c5ob01338k

  日期：——

  A Rh(iii)-catalyzed cyclization of azoles with alkynes has been developed to construct azole-fused-pyridines in good to excellent yields.

  已开发出一种Rh（III）催化的氮杂环与炔烃的环化反应，可在良好至优异的产率下构建杂环并联吡啶。
• FAP 저해제로서의 피롤리딘 유도체 및 이를 포함하는 약학적 조성물
  申请人：Boryung Corporation 주식회사 보령(119980015994) Corp. No ▼ 110111-0012560BRN ▼208-81-00281

  公开号：KR20200115934A

  公开（公告）日：2020-10-08

  본 발명은 FAP 저해제로서 하기 화학식 X로 나타내는, 피롤리딘 유도체 또는 그의 약학적으로 허용되는 염을 포함한다. [화학식 X]

  本发明涉及一种FAP抑制剂，包括用化学式X表示的吡啶衍生物或其药学上可接受的盐。 [化学式 X]
• CXCR7 ANTAGONISTS
  申请人：ChemoCentryx, Inc.

  公开号：US20140154179A1

  公开（公告）日：2014-06-05

  Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

  提供具有化学式I的化合物，或其药用可接受的盐、水合物或N-氧化物，并且这些化合物可用于与CXCR7结合，治疗部分或完全依赖于CXCR7活性的疾病。因此，根据本发明的进一步方面，提供含有上述化合物之一或多个的组合物与药用可接受的赋形剂混合物。
• [EN] PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVATIFS DE PYRIDINESULFONAMIDE POUVANT ÊTRE UTILISÉS COMME MODULATEURS TRAP1 ET LEURS UTILISATIONS
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188907A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了化合物的化学式（I）和药学上可接受的盐、溶剂化合物、水合物、多晶型、共晶体、互变异构体、立体异构体、同位素标记化合物以及其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能恢复PTEN诱导的激酶1（"PINK1"）功能丧失情况下的活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，和/或减少活性氧自由基的产生。所提供的化合物还可能对聚集或错误折叠的蛋白质（如α-突触核蛋白）进行重折叠或溶解。本公开还提供了包括所提供化合物的药物组合物；包括所提供化合物或药物组合物的试剂盒；以及使用所提供的化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• Design, synthesis, and optimization of a series of 2-azaspiro[3.3]heptane derivatives as orally bioavailable fetal hemoglobin inducers
  作者：Katsushi Katayama、Tomoyuki Tsunemi、Kazuo Miyazaki、Kouichi Uoto、Ryosuke Yoshioka、Hideki Terashima、Maki Terakawa、Kyoko Yamashiro、Munetada Haruyama、Hiroaki Maeda、Tomohiro Makino

  DOI：10.1016/j.bmcl.2020.127425

  日期：2020.10

  molecules that could induce HbF, which resulted in identification of the hit compound 1. Exploration of structure–activity relationships and optimization of ADME properties led to 2-azaspiro[3.3]heptane derivative 18, which is more rigid and has a unique structure. In vivo using cynomolgus monkeys, compound 18 induced a significant dose-dependent increase in globin switching, with developable properties

  γ-珠蛋白基因的药理学活化可用于胎儿血红蛋白（HbF）的产生，是治疗β地中海贫血和镰状细胞疾病（SCD）的有前途的方法。我们在人类红系祖细胞中进行了表型筛选，以鉴定可诱导HbF的分子，从而鉴定出了命中化合物1。对结构-活性关系的探索和ADME性质的优化导致了2-azaspiro [3.3]庚烷衍生物18的形成，该衍生物更刚性且具有独特的结构。在体内使用食蟹猴，化合物18诱导了球蛋白转换的显着剂量依赖性增加，具有可开发的特性。此外，化合物18表现出没有遗传毒性作用，并且比羟基脲安全得多。这些发现可以促进开发包括SCD在内的治疗β-血红蛋白病的有效新疗法。